Suppr超能文献

5-羟色胺再摄取抑制剂用于冠心病患者治疗抑郁症时的安全性如何?

How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease?

作者信息

Sheline Y I, Freedland K E, Carney R M

机构信息

Washington University School of Medicine, St Louis, Missouri 63110, USA.

出版信息

Am J Med. 1997 Jan;102(1):54-9. doi: 10.1016/s0002-9343(96)00374-9.

Abstract

Depression occurs frequently in patients with coronary heart disease (CHD), and confers significant risk for additional morbidity and mortality. The cardiac effects of the tricyclic antidepressants (TCAs) have been well characterized. In contrast, the cardiac effects of the selective serotonin reuptake inhibitors (SSRIs) have been less thoroughly investigated. The Medline database from 1986 to 1996 was searched for all reports of cardiac effects of SSRIs, and this literature is summarized. In addition, potential drug interactions, reports of side effects, and efficacy studies in the elderly are reviewed. Finally, recommendations are made considering the risk/benefit ratio.

摘要

抑郁症在冠心病(CHD)患者中频繁出现,并带来额外发病和死亡的重大风险。三环类抗抑郁药(TCA)的心脏效应已得到充分描述。相比之下,选择性5-羟色胺再摄取抑制剂(SSRI)的心脏效应研究得不够透彻。检索了1986年至1996年的医学文献数据库中所有关于SSRI心脏效应的报告,并对这些文献进行了总结。此外,还综述了潜在的药物相互作用、副作用报告以及老年人的疗效研究。最后,根据风险/效益比给出了建议。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验